Erasca Inc
ERAS
Company Profile
Business description
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Contact
3115 Merryfield Row
Suite 300
San DiegoCA92121
USAT: +1 858 465-6511
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
129
Stocks News & Analysis
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks
Could merger breathe new life into struggling ASX asset manager?
Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,815.30 | 5.00 | -0.06% |
CAC 40 | 7,808.17 | 21.12 | -0.27% |
DAX 40 | 24,165.67 | 89.64 | -0.37% |
Dow JONES (US) | 44,412.08 | 40.57 | 0.09% |
FTSE 100 | 8,998.06 | 56.94 | 0.64% |
HKSE | 24,203.32 | 63.75 | 0.26% |
NASDAQ | 20,623.63 | 38.11 | 0.19% |
Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
S&P 500 | 6,263.17 | 3.42 | 0.05% |
S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
SSE Composite Index | 3,519.65 | 9.47 | 0.27% |